{"id":50579,"date":"2018-01-02T22:29:51","date_gmt":"2018-01-03T06:29:51","guid":{"rendered":"http:\/\/69.46.6.243\/?p=50579"},"modified":"2018-01-02T22:29:51","modified_gmt":"2018-01-03T06:29:51","slug":"diabetes-drug-significantly-reverses-memory-loss-in-mice-with-alzheimers","status":"publish","type":"post","link":"https:\/\/new.thepinetree.net\/?p=50579","title":{"rendered":"Diabetes Drug &#8216;Significantly Reverses Memory Loss&#8217; in Mice with Alzheimer&#8217;s"},"content":{"rendered":"<p>Lancaster, UK&#8230;A drug developed for diabetes could be used to treat Alzheimer&#8217;s after scientists found it &#8220;significantly reversed memory loss&#8221; in mice through a triple method of action.  The research, published in Brain Research, could bring substantial improvements in the treatment of Alzheimer&#8217;s disease through the use of a drug originally created to treat type 2 diabetes.  Lead researcher Professor Christian Holscher of Lancaster University in the UK said the novel treatment &#8220;holds clear promise of being developed into a new treatment for chronic neurodegenerative disorders such as Alzheimer&#8217;s disease.&#8221;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/new.thepinetree.net\/wp-content\/uploads\/2018\/01\/159071_web.jpg\" alt=\"\" width=\"640\" height=\"500\" class=\"alignnone size-full wp-image-50581\" srcset=\"https:\/\/new.thepinetree.net\/wp-content\/uploads\/2018\/01\/159071_web.jpg 640w, https:\/\/new.thepinetree.net\/wp-content\/uploads\/2018\/01\/159071_web-300x234.jpg 300w, https:\/\/new.thepinetree.net\/wp-content\/uploads\/2018\/01\/159071_web-220x173.jpg 220w, https:\/\/new.thepinetree.net\/wp-content\/uploads\/2018\/01\/159071_web-570x445.jpg 570w, https:\/\/new.thepinetree.net\/wp-content\/uploads\/2018\/01\/159071_web-150x117.jpg 150w, https:\/\/new.thepinetree.net\/wp-content\/uploads\/2018\/01\/159071_web-500x391.jpg 500w\" sizes=\"auto, (max-width: 640px) 100vw, 640px\" \/><\/p>\n<p>Alzheimer&#8217;s disease is the most common cause of dementia and the numbers are expected to rise to two million people in the UK by 2051 according to Alzheimer&#8217;s Society, who part- funded the research.<\/p>\n<p>Dr Doug Brown, Director of Research and Development at Alzheimer&#8217;s Society, said: &#8220;&#8221;With no new treatments in nearly 15 years, we need to find new ways of tackling Alzheimer&#8217;s. It&#8217;s imperative that we explore whether drugs developed to treat other conditions can benefit people with Alzheimer&#8217;s and other forms of dementia. This approach to research could make it much quicker to get promising new drugs to the people who need them.&#8221;<\/p>\n<p>Although the benefits of these &#8216;triple agonist&#8217; drugs have so far only been found in mice, other studies with existing diabetes drugs such as liraglutide have shown real promise for people with Alzheimer&#8217;s, so further development of this work is crucial.&#8221;<\/p>\n<p>This is the first time that a triple receptor drug has been used which acts in multiple ways to protect the brain from degeneration. It combines GLP-1, GIP and Glucagon which are all growth factors. Problems with growth factor signalling have been shown to be impaired in the brains of Alzheimer&#8217;s patients.<\/p>\n<p>The study used APP\/PS1 mice, which are transgenic mice that express human mutated genes that cause Alzheimer&#8217;s. Those genes have been found in people who have a form of Alzheimer&#8217;s that can be inherited. Aged transgenic mice in the advanced stages of neurodegeneration were treated.<\/p>\n<p>In a maze test, learning and memory formation were much improved by the drug which also:-<\/p>\n<p>enhanced levels of a brain growth factor which protects nerve cell functioning<br \/>\nreduced the amount of amyloid plaques in the brain linked with Alzheimer&#8217;s<br \/>\nreduced both chronic inflammation and oxidative stress<br \/>\nslowed down the rate of nerve cell loss<br \/>\nProfessor Holscher said: &#8220;These very promising outcomes demonstrate the efficacy of these novel multiple receptor drugs that originally were developed to treat type 2 diabetes but have shown consistent neuro- protective effects in several studies.&#8221;<\/p>\n<p>&#8220;Clinical studies with an older version of this drug type already showed very promising results in people with Alzheimer&#8217;s disease or with mood disorders&#8221;<\/p>\n<p>&#8220;Here we show that a novel triple receptor drug shows promise as a potential treatment for Alzheimer&#8217;s but further dose-response tests and direct comparisons with other drugs have to be conducted in order to evaluate if this new drugs is superior to previous ones.&#8221;<\/p>\n<p>Type 2 diabetes is a risk factor for Alzheimer&#8217;s and has been implicated in the progression of the disease. Impaired insulin has been linked to cerebral degenerative processes in type 2 diabetes and Alzheimer&#8217;s disease. Insulin desensitisation has also been observed in the Alzheimer&#8217;s disease brain. The desensitisation could play a role in the development of neurodegenerative disorders as insulin is a growth factor with neuroprotective properties.<\/p>\n<p>###<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lancaster, UK&#8230;A drug developed for diabetes could be used to treat Alzheimer&#8217;s after scientists found it &#8220;significantly reversed memory loss&#8221; in mice through a triple method of action. The research, published in Brain Research, could bring substantial improvements in the treatment of Alzheimer&#8217;s disease through the use of a drug originally created to treat type [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":50581,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_cbd_carousel_blocks":"[]","jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[6,20,33,1],"tags":[],"class_list":["post-50579","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-education","category-featured","category-health-fitness","category-news","last_archivepost"],"jetpack_featured_media_url":"https:\/\/new.thepinetree.net\/wp-content\/uploads\/2018\/01\/159071_web.jpg","jetpack_sharing_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/new.thepinetree.net\/index.php?rest_route=\/wp\/v2\/posts\/50579","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/new.thepinetree.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/new.thepinetree.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/new.thepinetree.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/new.thepinetree.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50579"}],"version-history":[{"count":0,"href":"https:\/\/new.thepinetree.net\/index.php?rest_route=\/wp\/v2\/posts\/50579\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/new.thepinetree.net\/index.php?rest_route=\/wp\/v2\/media\/50581"}],"wp:attachment":[{"href":"https:\/\/new.thepinetree.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50579"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/new.thepinetree.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50579"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/new.thepinetree.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50579"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}